The National Institute for Health and Care Excellence (NICE) is currently updating its clinical guideline on the management of multiple sclerosis in primary and secondary care. Sativex is one of the new interventions which NICE has identified for inclusion in its updated guideline, which it currently expects to publish in October 2014.
In the absence of positive NICE technology appraisal guidance, national health service commissioners should make funding decisions based, on an assessment of the available evidence and on the basis of an individual patient's clinical circumstances.
In April 2013, under the Misuse of Drugs Regulations 2001 (as amended) the Home Office rescheduled Sativex, a cannabis based medicine, from a schedule 1 controlled drug to a part 1 schedule 4 controlled drug. The rescheduling reflects Sativex's low potential for abuse or diversion.